Selumetinib Paediatric NF1 Japan Phase 1 Study

Condition:   Neurofibromatosis Type 1 and Inoperable and Symptomatic Plexiform Neurofibroma Intervention:   Drug: Selumetinib Sponsor:   AstraZeneca Not yet recruiting

Source: ClinicalTrials.gov - July 31, 2020 Category: Research Source Type: clinical trials